Establish Tolerability with Oral Paliperidone or Risperidone Before Starting Invega Sustenna
For patients who have never taken oral paliperidone (Invega) or oral/injectable risperidone, you must establish tolerability with oral paliperidone or oral risperidone prior to initiating treatment with Invega Sustenna (paliperidone palmitate LAI). 1
No Specific Oral Dose Required
The FDA label does not specify a minimum oral dose or duration that patients must be stabilized on before transitioning to the LAI formulation. The requirement is simply to establish tolerability—meaning the patient can tolerate the medication without unacceptable adverse effects—not stabilization at a particular dose 1.
Practical Implementation
- Test tolerability with oral paliperidone extended-release tablets or oral risperidone for a brief period (typically several days to 1-2 weeks in clinical practice)
- Assess for hypersensitivity reactions, severe extrapyramidal symptoms, or other intolerable adverse effects
- Once tolerability is confirmed, initiate Invega Sustenna immediately using the standard loading dose regimen:
- Day 1: 234 mg deltoid injection
- Day 8: 156 mg deltoid injection
- Monthly maintenance: 39-234 mg (117 mg recommended for schizophrenia) 1
Important Caveats
For patients already taking oral paliperidone or risperidone: No tolerability testing is needed—proceed directly to LAI initiation 1.
Dose conversion reference (though not required for initiation): Patients on oral paliperidone 12 mg daily can transition to PP1M 234 mg monthly; 9 mg daily to 156 mg monthly; 6 mg daily to 117 mg monthly; 3 mg daily to 39-78 mg monthly 1. However, these are maintenance equivalents, not prerequisites for starting the LAI.
Renal impairment considerations: For mild renal impairment (CrCl 50-80 mL/min), use modified dosing (156 mg Day 1,117 mg Day 8, then 78 mg monthly maintenance). Invega Sustenna is not recommended for moderate-to-severe renal impairment 1.
The key distinction is that tolerability establishment is a safety checkpoint to identify patients who cannot tolerate the medication class, not a requirement for dose stabilization or symptom control before LAI initiation.